Euphausia superba fluorescein protease

By screening and cloning its luciferase gene from Antarctic krill, an Antarctic krill luciferase that emits blue fluorescence at a wavelength of 430nm-450nm was prepared, which solved the problem of insufficient research on marine bioluciferase and achieved the goal of Effective support for superficial tissue imaging in animals and extends the life of the enzyme with stability protectors.

CN119020333APending Publication Date: 2024-11-26YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411310409.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, research on marine bioluciferase, especially Antarctic krill luciferase, is relatively lacking, resulting in limited application of its medical detection and imaging technology, especially in superficial tissue imaging of animals. vesase options.

Method used

By screening and cloning its luciferase gene from Antarctic krill, a recombinant expression vector was constructed, and an Antarctic krill luciferase that emits blue fluorescence at a wavelength of 430nm-450nm was prepared, and through suitable protective agents Improves its stability and is used in fluorescence detection and imaging techniques.

Benefits of technology

It provides a new blue fluorescent emission luciferase suitable for superficial tissue imaging of animal, has a wide range of medical testing application prospects, and by improving the stability of the enzyme, it extends its service life and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020333A_ABST
    Figure CN119020333A_ABST
Patent Text Reader

Abstract

The invention provides euphausia superba luciferase. The amino acid sequence of the provided luciferase is SEQ ID NO: 1. The enzyme can emit blue fluorescence of 430-450 nm in the presence of oxygen, ATP (adenosine triphosphate) and magnesium ions. Compared with the yellow-green fluorescence emitted by the traditional firefly luciferase, the blue fluorescence has weak tissue penetrability, and has excellent application value in the field of animal superficial tissue imaging application. The Euphausia superba luciferase gene is cloned to a pCold-II expression vector, recombinant induced expression is carried out in Escherichia coli, recombinant luciferase with the molecular weight of 60 Kda can be obtained, and the recombinant luciferase can be applied to a living body biological fluorescence imaging technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of proteases, and in particular relates to Antarctic krill luciferin protease. Background Art

[0002] Luciferase is a general term for enzymes that can emit fluorescence in nature. They catalyze substrates to produce spontaneous fluorescence through enzymatic reactions. The emission wavelength of luciferase depends mainly on the type of luciferase used and its substrate. Luciferase can be divided into bacterial luciferase, beetle luciferase and luciferase extracted from marine organisms according to its source. Among them, researchers have done extensive and in-depth research on bacterial luciferase and beetle luciferase, but luciferase from marine animals, especially Antarctic krill, has not been reported. Antarctic krill is a key species in the Antarctic ecosystem, with a population density of 10,000-30,000 per cubic meter. In terms of biomass energy, they may be the animal species with the largest biomass on Earth (about 500 million tons in total). Antarctic krill have bioluminescent organs that can produce fluorescence. These organs are distributed in different parts of Antarctic krill: one pair in the eye column, another pair in the second to seventh thoracic legs, and one in the abdominal plate. This type of fluorescence mainly plays an important role in covering the shadows of Antarctic krill and mating or nighttime aggregation.

[0003] In vivo bioluminescence imaging technology is a rapidly developing gene expression detection method in recent years. Through image sensing instruments and analysis software, it can intuitively detect the fluorescent signal of ATP bioluminescence in the body and display it from the image. The highly sensitive in vivo imaging test involving luciferase can most directly monitor the development process of infectious diseases in living organisms, such as tracing bacteria and viruses marked with luciferase genes to understand their propagation laws in biological organisms; real-time observation of tumor growth and metastasis, such as a series of physiological processes of invasion, proliferation and spread of cancer cells transfected with luciferase genes in living organisms to understand the development mechanism of tumors. Therefore, obtaining luciferase with stable properties and excellent luminescence performance is of great significance for actual production and life.

[0004] The different maximum emission wavelengths of luciferases make them have different tissue penetration in the body and are suitable for different imaging needs. For example, firefly luciferase has better tissue penetration due to its yellow-green light, which is suitable for imaging tissues in deeper parts of animal viscera; while the blue light produced by Renilla luciferase has weaker tissue penetration and is suitable for imaging superficial tissues of animals. Since the fluorescence of luciferase with a longer emission wavelength is more difficult to be absorbed by skin tissue, it is more practical in in vivo imaging. Summary of the invention

[0005] The purpose of the present invention is to provide an Antarctic krill luciferase, as well as its encoding gene and recombinant expression method. The provided Antarctic krill luciferase has the function of using luciferin as a substrate, ATP to provide energy, and magnesium ions as a catalyst to emit specific blue fluorescence at a wavelength of 430nm-450nm.

[0006] The present invention first provides an Antarctic krill luciferase protease, wherein the Antarctic krill luciferase protease comprises: 1) a protease having an amino acid sequence of SEQ ID NO: 1; 2) A protease derived from 1) by replacing, deleting or adding one or more amino groups to the protease in 1); The protease in 2) mentioned above includes one amplified from Antarctic krill and is an isoenzyme with the protease in 1).

[0007] The present invention also provides a gene encoding the Antarctic krill luciferase protease, wherein a specific nucleotide sequence of the gene is SEQ ID NO:2.

[0008] The present invention also provides a recombinant expression vector, which contains the above gene fragment.

[0009] In yet another aspect, the present invention provides a recombinant engineering strain, wherein the recombinant engineering strain contains the above-mentioned recombinant expression vector.

[0010] As a specific description of the embodiment, the recombinant engineering strain is an Escherichia coli engineering strain.

[0011] Another aspect of the present invention also provides the use of the Antarctic krill luciferase in the preparation of fluorescence detection products.

[0012] The present invention also provides a bioluminescent luminescence system, wherein the system comprises the above-mentioned Antarctic krill luciferase and a fluorescent substrate; Furthermore, the fluorescent substrate is D-luciferin.

[0013] The luminescent system, as a specific example of the specification, comprises 25 mmol / L glycylglycine dipeptide, 5 mmol / L Mg 2+ , 1 mmol / L EDTA-Na2, 0.4% α-cyclodextrin, 0.15% diethylaminoethyl dextran, 20mmol / L Tris-HCL buffer, pH 7.2, 10 -6 mol / mL ATP, 10 -6 mol / mL D-luciferin and Antarctic krill luciferase.

[0014] The present invention further protects a stability protecting agent for recombinant Antarctic krill fluorescein prepared by the above-mentioned preparation method, wherein the optimal concentration of glycerol is 15%, the optimal concentration of BSA is 30 ug / ml, the optimal concentration of DTT is 0.3mmol / L, the optimal concentration of sorbitol is 5%, and the concentration of arabinose is 0.10 mol / L.

[0015] The luciferase screened by the present invention can emit specific blue fluorescence at a specific wavelength of 430nm-450nm under the condition that luciferin is used as a substrate, which has a wide application prospect in animal superficial tissue imaging in medical detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 : Electrophoresis of the nucleic acid of the Antarctic krill luciferase gene, where M:D2000 marker, lane 1 is the Antarctic krill luciferase gene; Figure 2 : Electrophoresis of Antarctic krill luciferase protein, where M is Marker (10-180Kda), lane 1 is blank control, and lane 2 is recombinant Antarctic krill luciferase; Figure 3 : Comparison of the stability of Antarctic krill luciferase, where series 1 is without protective agent and series 2 is with protective agent. DETAILED DESCRIPTION

[0017] The present invention screens a novel luciferase from Antarctic krill, which can emit 430nm-450nm blue fluorescence under the participation of oxygen, ATP and magnesium ions. The enzyme can provide rich options for fluorescence detection and imaging technology.

[0018] The present invention is described in detail below in conjunction with embodiments and drawings.

[0019] Example 1: Cloning of Antarctic krill luciferase gene and construction of expression vector Using the Antarctic krill cDNA genome sequence as a template, the Antarctic krill luciferase gene was amplified using KF / FR as primers (the primers contain EcoI and HindIII restriction sites). The agarose gel electrophoresis results of the PCR-amplified Antarctic krill luciferase are shown in Figure 2. Figure 1 As shown, the gene fragment is 1653 bp in length. The primers are as follows: KF: 5 ′ -GAATTCATGGCAAGCAGAGAGCCTCGAGTCC-3 ′ , FR: 5 ′-AAGCTTCAGTTTGGATTGTAATTTTGAGTATT-3 ′ .

[0020] The pCold-Ⅱ vector and the Antarctic krill luciferase gene were double-digested with EcoI and HindIII, and the digested products were recovered with a DNA product purification kit. The Antarctic krill luciferase gene and the double-digested pCold-Ⅱ vector were recombined using a ligase and transformed into DH5a competent cells. A single bacterium was picked the next day, and the positive recombinant clone was verified by bacterial liquid PCR. The positive clone was then subjected to DNA sequencing to verify the correctness of the gene sequence.

[0021] The amino acid sequence of the screened Antarctic krill luciferase protease was determined to be SEQ ID NO: 1, and the nucleotide sequence of the encoding gene thereof was determined to be SEQ ID NO: 2.

[0022] Example 2 Preparation of recombinant Antarctic krill luciferase Take 100 μL of the positive recombinant BL21(DE3) / pCold-Ⅱ luciferase bacterial solution identified by sequencing, inoculate it into 5.0 mL of LB liquid medium containing ampicillin, and culture it at 37°C overnight. The next day, take 50.0 μL and inoculate it into 50.0 mL of LB liquid medium containing ampicillin and continue to culture for 3-4 h (OD 600nm After the cell proliferation rate reached about 0.4-0.6), IPTG was added for induction with a final concentration of 1.0 mM. The cells were cultured overnight at 20°C and centrifuged at 8000 g for 5 min to collect the bacteria.

[0023] The cells were washed twice with 20mmol / L Tris-HCL phosphate buffer (pH 7.2), and then ultrasonically disrupted with 20mmol / L Tris-HCL phosphate buffer (pH 7.2). The cells were centrifuged at 12000g for 20min, and the supernatant was collected as the crude enzyme solution of recombinant Antarctic krill luciferase. The supernatant and the precipitate were detected by SDS-PAGE, and the BL21(DE3) / pCold-Ⅱ complete cell extract was used as a control ( Figure 2 ). The results showed that a recombinant Antarctic krill luciferase with a molecular weight of 60 KDa was obtained, and no target protein was expressed in the blank control. Therefore, the recombinant engineered bacteria prepared in this example can efficiently prepare Antarctic krill luciferase.

[0024] Example 3: Activity determination of recombinantly expressed Antarctic krill luciferase Luciferase catalyzes the reaction between ATP and luciferin in the presence of magnesium ions and oxygen molecules to emit fluorescence. The activity of luciferase is expressed by the relative luminescence intensity (RLU) of the catalytic reaction.

[0025] The luminescence intensity was measured by a bioluminescence detector from Promega. The detection was carried out at 25°C. 100 μL of the mixed solution (25 mmol / L glycylglycine dipeptide, 5 mmol / L Mg) was added to a 1.5 mL centrifuge tube. 2+ , 1mmol / L EDTA-Na2, 0.4% α-cyclodextrin, 0.15% diethylaminoethyl dextran, 20mmol / L Tris-HCL buffer, pH 7.2, 10 -6 mol / mL ATP, 10 -6 5 μL of Antarctic krill luciferase solution was added to 10 mol / mL D-luciferin. When the reaction started, the centrifuge tube was quickly placed in a bioluminescence detector. The reading was started after a delay of 2 s, and the fluorescence intensity at 10 s was recorded (Table 1). 7 RLU / mg of recombinant luciferase.

[0026] Table 1: Recombinant Antarctic krill luciferase activity assay strain BL21(DE3) / pCold-Ⅱ BL21(DE3) / pCold-Ⅱ-luciferase Antarctic krill luciferase activity 3.1 RLU / mg <![CDATA[2.3ⅹ10 7 RLU / mg]]> Example 4: Antarctic krill luciferase stability experiment Luciferase is extremely sensitive to factors such as temperature and freeze-thaw. It needs to be packaged and stored in a -20°C refrigerator before use, otherwise it is very easy to inactivate. Due to the instability of luciferase, the development and application of its products are greatly restricted. The present invention provides an optimal dosage of an Antarctic krill luciferase protective agent: the optimal concentration of glycerol is 15%, the optimal concentration of BSA is 30 ug / ml, the optimal concentration of DTT is 0.3mmol / L, the optimal concentration of sorbitol is 5%, and the concentration of arabinose is 0.10 mol / L. ( Figure 3 ) From this example, it can be seen that when several single preparations are mixed at a certain concentration and ratio and added to the luciferase system, the activity of the recombinant luciferase is still maintained at more than 75% after 25 hours, and the activity of the luciferase without the protective agent has basically decayed to zero after 25 hours. These protective agents are inexpensive and can be widely used as luciferase-related products.

[0027] The recombinant luciferase obtained by the present invention is oxidized to Mg 2+With the participation of luciferin, it catalyzes luciferin to emit blue fluorescence at a wavelength of 430nm-450nm. This reaction requires the participation of ATP. Since the luminescence intensity of the reaction is positively correlated with the ATP concentration within a certain concentration range, and ATP is widely and stably present in living cells, its content can indicate the number of microorganisms in food and processing environments, so luciferase can be used for rapid detection of microbial indicators in food production processes and food products. In addition, in vivo biological fluorescence imaging technology is a rapidly developing gene expression detection method in recent years. Through CCD (charge-coupled-device) image sensor instruments and analysis software, it can intuitively detect the fluorescent signal of ATP bioluminescence in organisms and display it from the image. The highly sensitive in vivo imaging test involving luciferase can most directly monitor the development process of infectious diseases in living organisms, such as tracing bacteria and viruses marked with luciferase genes to understand their propagation laws in biological organisms; real-time observation of tumor growth and metastasis, such as a series of physiological processes of invasion, proliferation and spread of cancer cells transfected with luciferase genes in living organisms to understand the development mechanism of tumors. Therefore, the luciferase with stable properties and excellent luminescence performance obtained by the present invention is of great significance for practical production and life.

Claims

1. An Antarctic krill luciferase, characterized in that The Antarctic krill luciferase contains: 1) a protease having an amino acid sequence of SEQ ID NO: 1; 2) A protease derived from 1) by replacing, deleting or adding one or more amino groups to the protease in 1).

2. The Antarctic krill luciferase according to claim 1, characterized in that The protease in 2) mentioned above includes one amplified from Antarctic krill and is an isoenzyme with the protease in 1).

3. A gene, characterized in that The gene encodes the Antarctic krill luciferase according to claim 1.

4. The gene according to claim 3, characterized in that The nucleotide sequence of the gene is SEQ ID NO:

2.

5. A recombinant expression vector, characterized in that: The recombinant expression vector contains the nucleic acid fragment of the gene according to claim 3.

6. A recombinant engineering strain, characterized in that: The recombinant engineering strain contains the recombinant expression vector according to claim 5.

7. Use of the Antarctic krill luciferase according to claim 1 in the preparation of fluorescence detection products.

8. A bioluminescent luminescence system, characterized in that: The system comprises the Antarctic krill luciferase and the fluorescent substrate as claimed in claim 1.

9. The light emitting system according to claim 8, characterized in that The luminescent system comprises 25 mmol / L glycylglycine dipeptide, 5 mmol / L Mg 2+ , 1 mmol / L EDTA-Na2, 0.4% α-cyclodextrin, 0.15% diethylaminoethyl dextran, 20mmol / L Tris-HCL buffer, pH 7.2, 10 -6 mol / mL ATP, 10 -6 mol / mL D-luciferin and the Antarctic krill luciferase according to claim 1.

10. The light emitting system according to claim 9, characterized in that The luminescent system further comprises a stability protecting agent, wherein the concentration of glycerol is 15%, the concentration of BSA is 30µg / ml, the concentration of DTT is 0.3mmol / L, the concentration of sorbitol is 5%, and the concentration of arabinose is 0.10 mol / L.

Citation Information

Cited By

  • Euphausia superba luciferase mutant

    CN119570753A

  • A luciferase mutant of Antarctic krill

    CN119570753B